Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:sorafenib
go back to main search page
Accession:CHEBI:50924 term browser browse the term
Definition:A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group.
Synonyms:exact_synonym: 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
 related_synonym: 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide;   Formula=C21H16ClF3N4O3;   InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31);   InChIKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N;   N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea;   SMILES=C1(=C(C=C(C=C1)NC(NC2=CC=C(C=C2)OC3=CC=NC(=C3)C(NC)=O)=O)C(F)(F)F)Cl;   sorafenibum
 alt_id: CHEBI:47228
 xref: CAS:284461-73-0;   DrugBank:DB00398;   Drug_Central:2459;   KEGG:D08524;   LINCS:LSM-1008
 xref_mesh: MESH:C471405
 xref: PDBeChem:BAX;   PMID:18520294;   PMID:19568496;   PMID:19633425;   PMID:19821497;   PMID:36029544;   Wikipedia:Sorafenib


show annotations for term's descendants           Sort by:
sorafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO sorafenib results in decreased activity of ABCB11 protein CTD PMID:20829430 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO [SNHG1 protein affects the susceptibility to Sorafenib] which affects the expression of ABCB1 protein CTD PMID:37927237 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 affects response to substance ISO ABCC1 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 affects response to substance
multiple interactions		 ISO ABCC2 affects the susceptibility to sorafenib
[SNHG1 protein affects the susceptibility to Sorafenib] which affects the expression of ABCC2 protein		 CTD PMID:24244338 PMID:37927237 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 affects response to substance ISO ABCC3 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases phosphorylation
decreases activity		 ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of ABL1 protein mutant form
sorafenib results in decreased activity of ABL1 protein mutant form		 CTD PMID:19366808 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065 		JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTA2 mRNA CTD PMID:24321339 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Actg2 actin gamma 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTG2 mRNA CTD PMID:19338580 NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465 		JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] CTD PMID:29859236 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480 		JBrowse link
G Ahr aryl hydrocarbon receptor affects localization ISO Sorafenib affects the localization of AHR protein CTD PMID:35124147 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
affects localization		 ISO [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] affects the localization of AIFM1 protein; [sorafenib co-treated with 6-bromoindirubin-3'-oxime] affects the localization of AIFM1 protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]
Sorafenib affects the localization of AIFM1 protein		 CTD PMID:16109713 PMID:16959960 PMID:17909059 PMID:17991738 PMID:20054642 More... NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
increases phosphorylation
decreases expression		 ISO
EXP		 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Sorafenib results in decreased phosphorylation of AKT1 protein]; [antrocin analog co-treated with Sorafenib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with Sorafenib] results in decreased phosphorylation of AKT1 protein; [Methionine co-treated with Sorafenib] results in decreased phosphorylation of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with Sorafenib]; Oxygen deficiency affects the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [Sorafenib results in decreased phosphorylation of AKT1 protein]]
sorafenib results in decreased phosphorylation of AKT1 protein
Sorafenib results in increased phosphorylation of AKT1 protein
Sorafenib analog results in decreased expression of AKT1 protein
[Sorafenib co-treated with Methionine] inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of AKT1 protein]		 CTD PMID:16985072 PMID:21858812 PMID:23036488 PMID:36565974 PMID:38367245 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ascl4 achaete-scute family bHLH transcription factor 4 multiple interactions
increases expression		 ISO [arsenic disulfide co-treated with Sorafenib] results in increased expression of ASCL4 protein
Sorafenib results in increased expression of ASCL4 protein		 CTD PMID:36321791 NCBI chr 7:17,940,972...17,943,215
Ensembl chr 7:17,941,709...17,942,146 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression		 ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of ATF4 mRNA; sorafenib results in increased expression of ATF4 protein		 CTD PMID:21601561 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression		 ISO [Sorafenib co-treated with Vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein; ATG5 protein inhibits the reaction [[Sorafenib co-treated with Vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]
sorafenib results in increased expression of ATG5 protein		 CTD PMID:18787411 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
decreases expression		 ISO sorafenib results in increased expression of BAD protein
sorafenib results in decreased expression of BAD mRNA		 CTD PMID:18200035 PMID:21360571 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 decreases expression
increases expression
multiple interactions		 ISO sorafenib results in decreased expression of BAK1 protein
sorafenib results in increased expression of BAK1 protein
[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of BAK1 protein]		 CTD PMID:16109713 PMID:17909059 PMID:18200035 PMID:24434019 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression		 ISO [antrocin analog co-treated with Sorafenib] results in increased expression of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; BCL2L1 protein inhibits the reaction [Sorafenib affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; Sorafenib affects the folding of and results in increased activity of BAX protein
sorafenib results in increased expression of BAX protein
sorafenib results in increased cleavage of BAX protein
sorafenib results in decreased expression of BAX mRNA		 CTD PMID:16109713 PMID:17909059 PMID:18200035 PMID:19366808 PMID:21360571 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
increases cleavage
decreases response to substance		 ISO [Paclitaxel co-treated with sorafenib] results in decreased expression of BCL2 protein; [sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2 protein]; sorafenib inhibits the reaction [Acids results in increased expression of BCL2 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2 protein]
sorafenib results in decreased expression of BCL2 mRNA; sorafenib results in decreased expression of BCL2 protein
sorafenib results in increased cleavage of BCL2 protein
BCL2 protein results in decreased susceptibility to sorafenib		 CTD PMID:16109713 PMID:17991738 PMID:18512153 PMID:19664330 PMID:19878585 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression		 ISO [sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2L1 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2L1 protein]
Sorafenib results in decreased expression of BCL2L1 protein		 CTD PMID:16109713 PMID:17909059 PMID:17991738 PMID:19366808 PMID:19633425 More... NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 affects localization
multiple interactions
decreases expression
increases expression		 ISO sorafenib affects the localization of BCL2L11 protein
[sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of BCL2L11 protein
sorafenib results in decreased expression of BCL2L11 protein
sorafenib results in increased expression of BCL2L11 protein		 CTD PMID:16109713 PMID:18200035 PMID:23036488 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions
decreases activity
decreases phosphorylation		 ISO sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased activity of BCR protein mutant form
sorafenib results in decreased phosphorylation of BCR protein mutant form		 CTD PMID:19366808 NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of BID protein CTD PMID:17909059 PMID:20301194 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO sorafenib results in decreased expression of BIRC3 protein CTD PMID:20473320 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression		 ISO [[[Sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [Resveratrol co-treated with Sorafenib] results in decreased expression of BIRC5 protein; Sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein]
sorafenib analog results in decreased expression of BIRC5 protein; sorafenib results in decreased expression of BIRC5 mRNA; sorafenib results in decreased expression of BIRC5 protein		 CTD PMID:18200035 PMID:20473320 PMID:21531053 PMID:21601561 PMID:26172295 More... NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
decreases activity		 ISO
EXP		 Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]
sorafenib results in decreased activity of BRAF protein; sorafenib results in decreased activity of BRAF protein mutant form		 CTD PMID:17341847 PMID:17664273 PMID:20823850 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463 		JBrowse link
G Cald1 caldesmon 1 multiple interactions EXP Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of CALD1 protein] CTD PMID:36731809 NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Sorafenib results in increased activity of CASP1 protein]; Sorafenib results in increased cleavage of and results in increased activity of CASP1 protein CTD PMID:33271325 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 multiple interactions
affects cleavage
decreases expression
increases activity
increases cleavage
increases expression		 ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of CASP3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CASP3 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP3 protein
sorafenib affects the cleavage of CASP3 protein
sorafenib results in decreased expression of CASP3 mRNA
Sorafenib results in increased expression of CASP3 protein modified form		 CTD PMID:16007148 PMID:16109713 PMID:16985072 PMID:17909059 PMID:18200035 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions		 ISO sorafenib results in increased activity of CASP7 protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; sorafenib results in increased cleavage of and results in increased activity of CASP7 protein		 CTD PMID:16109713 PMID:17909059 PMID:19770576 PMID:20054642 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 multiple interactions
affects localization
increases cleavage		 ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP8 protein; [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein; ATG5 protein inhibits the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; sorafenib results in increased cleavage of and results in increased activity of CASP8 protein
sorafenib affects the localization of CASP8 protein modified form
sorafenib results in increased cleavage of CASP8 protein		 CTD PMID:16007148 PMID:16109713 PMID:17909059 PMID:18200035 PMID:18787411 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
increases cleavage		 ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP9 protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP9 protein
sorafenib results in increased cleavage of CASP9 protein		 CTD PMID:16109713 PMID:16985072 PMID:17909059 PMID:18200035 PMID:20054642 More... NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression ISO Sorafenib results in decreased expression of CCN2 mRNA CTD PMID:21360571 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO sorafenib results in decreased expression of CCNA2 protein CTD PMID:19139124 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO sorafenib results in decreased expression of CCNB1 protein CTD PMID:19139124 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions		 ISO
EXP		 sorafenib analog results in decreased expression of CCND1 protein; sorafenib results in decreased expression of CCND1 mRNA; sorafenib results in decreased expression of CCND1 protein
[sorafenib co-treated with letrozole] results in decreased expression of CCND1 protein; [sorafenib co-treated with rottlerin] results in decreased expression of CCND1 protein; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CCND1 protein]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CCND1 protein]
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein]
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]		 CTD PMID:16959960 PMID:17178882 PMID:17909054 PMID:18512153 PMID:18840136 More... NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO sorafenib results in decreased expression of CCND2 protein CTD PMID:19001435 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495 		JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases expression		 ISO [sorafenib co-treated with rottlerin] results in decreased expression of CCND3 protein
sorafenib results in decreased expression of CCND3 protein		 CTD PMID:16959960 PMID:19001435 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371 		JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO sorafenib inhibits the reaction [Acids results in increased expression of CCNE1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression		 ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of CDH1 protein]
sorafenib results in increased expression of CDH1 protein		 CTD PMID:21360571 PMID:24434019 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CDH2 protein] CTD PMID:24434019 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO sorafenib results in decreased expression of CDK1 protein CTD PMID:19139124 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO sorafenib results in decreased expression of CDK2 mRNA CTD PMID:26409325 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions
decreases expression		 ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK4 protein
sorafenib results in decreased expression of CDK4 protein		 CTD PMID:16959960 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression		 ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK6 protein
sorafenib results in decreased expression of CDK6 protein		 CTD PMID:16959960 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdk9 cyclin-dependent kinase 9 decreases expression ISO sorafenib results in decreased expression of CDK9 mRNA CTD PMID:26409325 NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO sorafenib results in decreased expression of CDKN1A protein CTD PMID:19139124 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression
decreases expression		 ISO
EXP		 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in increased expression of CDKN1B protein]; sorafenib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of CDKN1B protein]
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein]
sorafenib results in decreased expression of CDKN1B protein		 CTD PMID:19139124 PMID:19878585 PMID:21693435 PMID:23036488 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO sorafenib results in increased expression of CDKN2B protein CTD PMID:19139124 NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions
increases expression		 ISO sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
sorafenib results in increased expression of CEBPD protein		 CTD PMID:26172295 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression
multiple interactions
increases degradation		 ISO sorafenib results in decreased expression of CFLAR protein
[sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein		 CTD PMID:17909059 PMID:20071162 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression		 ISO
EXP		 Sorafenib inhibits the reaction [Oleic Acid results in increased expression of COL1A1 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
sorafenib results in decreased expression of COL1A1 mRNA		 CTD PMID:21360571 PMID:24321339 PMID:32918399 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein] CTD PMID:21360571 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547 		JBrowse link
G Col4a1 collagen type IV alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein] CTD PMID:21360571 NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of CPT1A mRNA] CTD PMID:32918399 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions
decreases phosphorylation		 ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of CRKL protein		 CTD PMID:19366808 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CTNNB1 protein] CTD PMID:24434019 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cycs cytochrome c, somatic affects localization ISO sorafenib affects the localization of CYCS protein CTD PMID:16007148 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyld CYLD lysine 63 deubiquitinase increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; sorafenib results in increased expression of CYLD mRNA; sorafenib results in increased expression of CYLD protein CTD PMID:21109933 NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity
decreases expression
multiple interactions		 ISO Sorafenib results in decreased activity of CYP1A1 protein
Sorafenib results in decreased expression of CYP1A1 mRNA; Sorafenib results in decreased expression of CYP1A1 protein
Sorafenib inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of CYP1A1 mRNA]; Sorafenib inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of CYP1A1 protein]; Sorafenib inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Sorafenib inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 protein]		 CTD PMID:33814510 PMID:35124147 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Sorafenib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO Sorafenib metabolite results in decreased activity of CYP2C8 protein; Sorafenib results in decreased activity of CYP2C8 protein CTD PMID:33556367
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects metabolic processing ISO CYP3A5 protein polymorphism affects the metabolism of Sorafenib CTD PMID:35099304 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; sorafenib results in increased expression of DDIT3 mRNA; sorafenib results in increased expression of DDIT3 protein CTD PMID:17548474 PMID:21601561 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 multiple interactions
increases expression		 ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of DDIT4 protein		 CTD PMID:21601561 NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions
affects localization		 ISO 6-bromoindirubin-3'-oxime promotes the reaction [sorafenib affects the localization of DIABLO protein]; [sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]
Sorafenib affects the localization of DIABLO protein		 CTD PMID:17909059 PMID:17991738 NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387 		JBrowse link
G Dok1 docking protein 1 decreases phosphorylation ISO sorafenib results in decreased phosphorylation of DOK1 protein CTD PMID:19366808 NCBI chr 4:115,537,453...115,540,464
Ensembl chr 4:115,537,462...115,540,465 		JBrowse link
G Dusp3 dual specificity phosphatase 3 multiple interactions ISO
EXP		 [Methionine co-treated with Sorafenib] results in increased expression of DUSP3 mRNA
[Sorafenib co-treated with Methionine] inhibits the reaction [Diethylnitrosamine results in decreased expression of DUSP3 mRNA]		 CTD PMID:38367245 NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962 		JBrowse link
G Ece1 endothelin converting enzyme 1 increases expression EXP Sorafenib results in increased expression of ECE1 protein CTD PMID:33503445 NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371 		JBrowse link
G Edn1 endothelin 1 increases expression EXP Sorafenib results in increased expression of EDN1 protein CTD PMID:33503445 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885 		JBrowse link
G Ednrb endothelin receptor type B increases expression EXP Sorafenib results in increased expression of EDNRB mRNA; Sorafenib results in increased expression of EDNRB protein CTD PMID:33503445 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:17664273 PMID:21187475 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor decreases expression ISO sorafenib results in decreased expression of EGFR mRNA CTD PMID:26409325 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases phosphorylation		 ISO [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]
sorafenib results in increased phosphorylation of EIF2A protein		 CTD PMID:17548474 PMID:18787411 PMID:19366808 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
increases phosphorylation		 ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]
sorafenib results in increased phosphorylation of EIF2AK3 protein		 CTD PMID:17548474 PMID:18787411 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
decreases phosphorylation		 ISO [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713 PMID:21750559 NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
decreases phosphorylation
increases phosphorylation		 ISO
EXP		 [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased phosphorylation of EIF4EBP1 protein; arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of EIF4EBP1 protein]
Sorafenib results in decreased phosphorylation of EIF4EBP1 protein
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]		 CTD PMID:16255777 PMID:20054642 PMID:21601561 PMID:21813464 PMID:21858812 More... NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984 		JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO EZH2 protein affects the reaction [MIR600 affects the susceptibility to Sorafenib] CTD PMID:38229326 NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362 		JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein] CTD PMID:18787411 NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [vorinostat co-treated with sorafenib] affects the localization of FAS protein; [vorinostat co-treated with sorafenib] results in increased activity of FAS protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; fumonisin B1 inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein]; thermozymocidin inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein] CTD PMID:18787411 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Faslg Fas ligand multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein] CTD PMID:20301194 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 increases response to substance
decreases activity
multiple interactions
decreases phosphorylation		 ISO FLT3 protein results in increased susceptibility to sorafenib
sorafenib results in decreased activity of FLT3 protein; sorafenib results in decreased activity of FLT3 protein mutant form
[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of FLT3 protein mutant form; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of FLT3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]
sorafenib results in decreased phosphorylation of FLT3 protein mutant form		 CTD PMID:17205056 PMID:17229632 PMID:21482694 PMID:22409268 PMID:23036488 NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] CTD PMID:21360571 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions
increases response to substance
increases expression		 ISO pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased localization of GADD45B protein
GADD45B protein results in increased susceptibility to sorafenib		 CTD PMID:21062976 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases response to substance
multiple interactions
increases expression		 ISO GADD45G mutant form results in decreased susceptibility to sorafenib
sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
sorafenib results in increased expression of GADD45G mRNA; sorafenib results in increased expression of GADD45G protein		 CTD PMID:26172295 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases secretion		 ISO
EXP		 Sorafenib inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]
Sorafenib results in increased secretion of GPT protein
[Sorafenib co-treated with Methionine] inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]		 CTD PMID:29655783 PMID:29859236 PMID:38367245 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions		 ISO Sorafenib results in decreased expression of GPX4 protein
Sorafenib promotes the reaction [arsenic disulfide results in decreased expression of GPX4 protein]		 CTD PMID:36321791 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982 		JBrowse link
G Grb2 growth factor receptor bound protein 2 decreases expression ISO sorafenib results in decreased expression of GRB2 mRNA CTD PMID:26409325 NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309 		JBrowse link
G Gsdmd gasdermin D increases expression ISO Sorafenib results in increased expression of GSDMD protein CTD PMID:33271325 NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases phosphorylation		 ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of GSK3B protein]; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]; sorafenib inhibits the reaction [arsenic trioxide results in decreased phosphorylation of GSK3B protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein]; sorafenib results in decreased phosphorylation of and results in increased activity of GSK3B protein CTD PMID:17991738 PMID:25416439 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Hdac6 histone deacetylase 6 decreases expression ISO sorafenib results in decreased expression of HDAC6 mRNA CTD PMID:26409325 NCBI chr  X:14,550,645...14,572,445
Ensembl chr  X:14,551,044...14,572,441 		JBrowse link
G Hgf hepatocyte growth factor decreases response to substance
multiple interactions		 ISO HGF protein results in decreased susceptibility to Sorafenib
Plant Extracts inhibits the reaction [HGF protein results in decreased susceptibility to Sorafenib]		 CTD PMID:32522589 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression ISO sorafenib results in decreased expression of HIF1A mRNA CTD PMID:26409325 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hk2 hexokinase 2 multiple interactions ISO [SNHG1 protein affects the susceptibility to Sorafenib] which affects the expression of HK2 protein CTD PMID:37927237 NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530 		JBrowse link
G Hmgb1 high mobility group box 1 increases expression ISO Sorafenib results in increased expression of HMGB1 protein CTD PMID:33271325 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565 		JBrowse link
G Hoxd10 homeo box D10 increases expression
multiple interactions		 ISO Sorafenib results in increased expression of HOXD10 protein
[Sorafenib co-treated with Ropivacaine] results in increased expression of HOXD10 protein; MIR224 inhibits the reaction [[Sorafenib co-treated with Ropivacaine] results in increased expression of HOXD10 protein]		 CTD PMID:38197552 NCBI chr 3:59,594,516...59,597,725
Ensembl chr 3:59,594,516...59,597,725 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]] CTD PMID:18787411 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein] CTD PMID:21601561 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296 		JBrowse link
G Igf1r insulin-like growth factor 1 receptor decreases expression ISO sorafenib results in decreased expression of IGF1R mRNA CTD PMID:26409325 NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777 		JBrowse link
G Il1b interleukin 1 beta increases secretion
multiple interactions		 ISO Sorafenib results in increased secretion of IL1B protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Sorafenib results in increased secretion of IL1B protein]		 CTD PMID:33271325 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of IL6 protein] CTD PMID:32918399 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Irf5 interferon regulatory factor 5 increases expression ISO sorafenib results in increased expression of IRF5 mRNA CTD PMID:26409325 NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression		 ISO [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; [sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased phosphorylation of and results in increased localization of JUN protein CTD PMID:16985072 PMID:20301194 PMID:21062976 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO sorafenib results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions
decreases phosphorylation		 ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein
sorafenib results in decreased phosphorylation of KDR protein		 CTD PMID:16985072 PMID:19139124 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of KIT protein CTD PMID:19139124 NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652 		JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of LCK protein CTD PMID:21293487 NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794 		JBrowse link
G Lipc lipase C, hepatic type multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of LIPC mRNA] CTD PMID:32918399 NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
decreases phosphorylation		 ISO
EXP		 [MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]
sorafenib results in decreased phosphorylation of MAP2K1 protein		 CTD PMID:17341847 PMID:18200035 PMID:19139124 PMID:20117835 PMID:21187475 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions
decreases phosphorylation		 ISO
EXP		 [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]
sorafenib results in decreased phosphorylation of MAP2K2 protein		 CTD PMID:17341847 PMID:18200035 PMID:21187475 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions
decreases phosphorylation		 ISO licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAP2K4 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAP2K4 protein] CTD PMID:30187994 NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 affects phosphorylation
multiple interactions
decreases activity
decreases phosphorylation
decreases expression
increases phosphorylation		 ISO
EXP		 sorafenib affects the phosphorylation of MAPK1 protein
[antrocin analog co-treated with Sorafenib] results in decreased expression of MAPK1 protein; [MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to Sorafenib; [Methionine co-treated with Sorafenib] results in decreased phosphorylation of MAPK1 protein; [Sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK1 protein; [Sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK1 protein; [Sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [Sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK1 protein; [Sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein; [Sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [Sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; Sorafenib inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK1 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
sorafenib results in decreased activity of MAPK1 protein
Sorafenib results in decreased phosphorylation of MAPK1 protein
sorafenib results in decreased expression of MAPK1 protein modified form
[Sorafenib co-treated with Methionine] inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]; Sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
sorafenib results in decreased phosphorylation of MAPK1 protein
sorafenib results in increased phosphorylation of MAPK1 protein		 CTD PMID:16109713 PMID:16255777 PMID:16959960 PMID:17178882 PMID:17205056 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases expression ISO sorafenib results in decreased expression of MAPK14 protein modified form CTD PMID:16985072 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
affects phosphorylation
decreases activity
decreases phosphorylation
decreases expression
increases phosphorylation		 ISO
EXP		 [antrocin analog co-treated with Sorafenib] results in decreased expression of MAPK3 protein; [MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to Sorafenib; [Methionine co-treated with Sorafenib] results in decreased phosphorylation of MAPK3 protein; [Sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK3 protein; [Sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK3 protein; [Sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [Sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK3 protein; [Sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK3 protein; [Sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [Sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; Sorafenib inhibits the reaction [Acids results in increased phosphorylation of MAPK3 protein]; Sorafenib inhibits the reaction [Arsenic Trioxide results in increased activity of MAPK3 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
sorafenib affects the phosphorylation of MAPK3 protein
sorafenib results in decreased activity of MAPK3 protein
Sorafenib results in decreased phosphorylation of MAPK3 protein
[Sorafenib co-treated with Methionine] inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]; Sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib results in decreased expression of MAPK3 protein modified form
sorafenib results in increased phosphorylation of MAPK3 protein		 CTD PMID:16109713 PMID:16255777 PMID:16959960 PMID:17178882 PMID:17205056 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases phosphorylation		 ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK8 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK8 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK8 protein] CTD PMID:16985072 PMID:30187994 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
decreases phosphorylation		 ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK9 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK9 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK9 protein] CTD PMID:16985072 PMID:30187994 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
decreases response to substance
decreases expression
increases degradation
affects response to substance		 ISO [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased expression of MCL1 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 mRNA; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; MCL1 protein results in decreased susceptibility to [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide]; sorafenib results in increased degradation of and results in decreased expression of MCL1 protein
MCL1 protein results in decreased susceptibility to sorafenib
sorafenib results in decreased expression of MCL1 protein
sorafenib results in increased degradation of MCL1 protein
MCL1 protein affects the susceptibility to sorafenib		 CTD PMID:16007148 PMID:16109713 PMID:16985072 PMID:17178882 PMID:17595328 More... NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO sorafenib results in increased expression of MDM2 mRNA CTD PMID:26409325 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Mir224 microRNA 224 decreases expression
multiple interactions		 ISO Sorafenib results in decreased expression of MIR224 mRNA
MIR224 inhibits the reaction [[Sorafenib co-treated with Ropivacaine] results in increased expression of HOXD10 protein]; Ropivacaine promotes the reaction [Sorafenib results in decreased expression of MIR224 mRNA]		 CTD PMID:38197552 NCBI chr  X:150,065,088...150,065,169
Ensembl chr  X:150,065,088...150,065,169 		JBrowse link
G Mir93 microRNA 93 decreases response to substance ISO MIR93 results in decreased susceptibility to Sorafenib CTD PMID:38375688 NCBI chr12:17,043,135...17,043,221
Ensembl chr12:17,043,135...17,043,221 		JBrowse link
G Mknk1 MAPK interacting serine/threonine kinase 1 multiple interactions ISO sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713 NCBI chr 5:129,318,128...129,357,641
Ensembl chr 5:129,318,170...129,357,639 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] CTD PMID:29859236 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Msn moesin increases phosphorylation EXP sorafenib results in increased phosphorylation of MSN protein CTD PMID:19338580 NCBI chr  X:60,996,043...61,064,011
Ensembl chr  X:60,995,951...61,065,628 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases activity
decreases expression
multiple interactions
decreases phosphorylation
increases expression
increases phosphorylation		 ISO sorafenib results in decreased activity of MTOR protein
sorafenib results in decreased expression of MTOR mRNA
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased activity of MTOR protein; [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; arsenic trioxide inhibits the reaction [sorafenib results in increased expression of MTOR protein]
sorafenib results in decreased phosphorylation of MTOR protein
sorafenib results in increased phosphorylation of MTOR protein		 CTD PMID:20054642 PMID:21187475 PMID:21601561 PMID:23036488 PMID:25416439 More... NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Mttp microsomal triglyceride transfer protein multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in decreased expression of MTTP mRNA] CTD PMID:32918399 NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [sorafenib co-treated with letrozole] results in decreased expression of MYC protein; sorafenib inhibits the reaction [Acids results in increased expression of MYC protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein] CTD PMID:17991738 PMID:18512153 PMID:20054642 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] CTD PMID:29859236 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein CTD PMID:21109933 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nos2 nitric oxide synthase 2 decreases expression EXP Sorafenib results in decreased expression of NOS2 mRNA CTD PMID:33503445 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nos3 nitric oxide synthase 3 decreases expression
multiple interactions		 EXP Sorafenib results in decreased expression of NOS3 mRNA
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of NOS3 protein]		 CTD PMID:33503445 PMID:36731809 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166 		JBrowse link
G Nras NRAS proto-oncogene, GTPase decreases expression ISO sorafenib results in decreased expression of NRAS mRNA CTD PMID:26409325 NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [desloratadine results in increased susceptibility to Sorafenib] which results in increased cleavage of PARP1 protein; [Sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; [Sorafenib results in increased susceptibility to desloratadine] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Sorafenib results in increased cleavage of PARP1 protein]
sorafenib results in increased cleavage of PARP1 protein		 CTD PMID:16985072 PMID:20054642 PMID:26911335 PMID:28673964 PMID:36617552 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of PDGFB mRNA] CTD PMID:32918399 NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984 		JBrowse link
G Pdgfra platelet derived growth factor receptor alpha decreases phosphorylation ISO sorafenib results in decreased phosphorylation of PDGFRA protein mutant form CTD PMID:21482694 NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta multiple interactions
decreases activity
decreases phosphorylation
decreases expression		 ISO
EXP		 [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased activity of PDGFRB protein mutant form
sorafenib results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased expression of PDGFRB mRNA
sorafenib results in decreased phosphorylation of and results in decreased activity of PDGFRB protein		 CTD PMID:16985072 PMID:17229632 PMID:19139124 PMID:19338580 NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 decreases expression EXP Sorafenib results in decreased expression of PECAM1 protein CTD PMID:33503445 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116 		JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha decreases expression ISO sorafenib results in decreased expression of PIK3C2A mRNA CTD PMID:26409325 NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472 		JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha decreases expression ISO sorafenib results in decreased expression of PIK3CA mRNA CTD PMID:26409325 NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032 		JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein]; [sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; sorafenib inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein] CTD PMID:23036488 NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174 		JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
affects response to substance
increases expression		 ISO [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
PINK1 protein affects the susceptibility to sorafenib
sorafenib results in increased expression of PINK1 protein		 CTD PMID:28673964 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Pkm pyruvate kinase M1/2 multiple interactions ISO [SNHG1 protein affects the susceptibility to Sorafenib] which affects the expression of PKM protein CTD PMID:37927237 NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599 		JBrowse link
G Plau plasminogen activator, urokinase decreases expression
multiple interactions		 ISO Sorafenib results in decreased expression of PLAU protein
licochalcone A promotes the reaction [Sorafenib results in decreased expression of PLAU protein]; Sorafenib promotes the reaction [licochalcone A results in decreased expression of PLAU protein]		 CTD PMID:30187994 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plk2 polo-like kinase 2 increases expression ISO sorafenib results in increased expression of PLK2 mRNA CTD PMID:26409325 NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947 		JBrowse link
G Plk3 polo-like kinase 3 increases expression ISO sorafenib results in increased expression of PLK3 mRNA CTD PMID:26409325 NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
decreases expression		 ISO 6-bromoindirubin-3'-oxime inhibits the reaction [sorafenib results in decreased expression of PMAIP1 protein] CTD PMID:17991738 NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO sorafenib results in increased expression of PPP1R15A protein CTD PMID:17548474 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171 		JBrowse link
G Prkca protein kinase C, alpha decreases expression ISO sorafenib results in decreased expression of PRKCA mRNA CTD PMID:26409325 NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase increases ubiquitination
affects localization
multiple interactions
affects response to substance		 ISO sorafenib results in increased ubiquitination of PRKN protein
sorafenib affects the localization of PRKN protein
[sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
PRKN protein affects the susceptibility to sorafenib		 CTD PMID:28673964 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases activity ISO sorafenib results in decreased activity of RAF1 protein CTD PMID:19139124 PMID:21531053 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases phosphorylation
decreases expression		 ISO [sorafenib co-treated with letrozole] results in decreased expression of RB1 protein
sorafenib results in decreased phosphorylation of RB1 protein
sorafenib results in decreased expression of RB1 protein		 CTD PMID:17909054 PMID:19633425 PMID:20054642 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] CTD PMID:29859236 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Ret ret proto-oncogene decreases activity
increases degradation		 ISO Sorafenib results in decreased activity of RET protein; Sorafenib results in decreased activity of RET protein mutant form
sorafenib results in increased degradation of RET protein		 CTD PMID:17664273 NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176 		JBrowse link
G Rock1 Rho-associated coiled-coil containing protein kinase 1 decreases expression
increases expression		 EXP sorafenib results in decreased expression of ROCK1 mRNA; sorafenib results in decreased expression of ROCK1 protein
sorafenib results in increased expression of ROCK1 protein		 CTD PMID:19338580 NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions		 ISO sorafenib results in decreased phosphorylation of RPS6 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of RPS6 protein]		 CTD PMID:23036488 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions
increases phosphorylation
decreases phosphorylation		 ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of RPS6KB1 protein]
Sorafenib results in decreased phosphorylation of RPS6KB1 protein		 CTD PMID:21858812 PMID:25416439 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Runx3 RUNX family transcription factor 3 multiple interactions ISO RUNX3 protein affects the reaction [MIR600 affects the susceptibility to Sorafenib] CTD PMID:38229326 NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156 		JBrowse link
G Serpinh1 serpin family H member 1 decreases expression EXP sorafenib results in decreased expression of SERPINH1 mRNA CTD PMID:24321339 NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801 		JBrowse link
G Sesn2 sestrin 2 increases expression ISO Sorafenib results in increased expression of SESN2 protein CTD PMID:31323261 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260 		JBrowse link
G Slc13a5 solute carrier family 13 member 5 decreases response to substance ISO SLC13A5 protein results in decreased susceptibility to Sorafenib CTD PMID:32634519 NCBI chr10:56,866,249...56,891,189
Ensembl chr10:56,866,249...56,890,945 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 multiple interactions
decreases expression		 ISO SLC7A11 protein affects the reaction [SNHG1 protein results in decreased susceptibility to Sorafenib]; Sorafenib promotes the reaction [arsenic disulfide results in decreased expression of SLC7A11 protein]
Sorafenib results in decreased expression of SLC7A11 protein		 CTD PMID:36321791 PMID:37927237 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536 		JBrowse link
G Smad2 SMAD family member 2 affects localization
multiple interactions		 ISO sorafenib affects the localization of SMAD2 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]		 CTD PMID:21360571 NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323 		JBrowse link
G Smad3 SMAD family member 3 affects localization
multiple interactions		 ISO sorafenib affects the localization of SMAD3 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]		 CTD PMID:21360571 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Smad7 SMAD family member 7 decreases expression ISO sorafenib results in decreased expression of SMAD7 mRNA CTD PMID:21360571 NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765 		JBrowse link
G Smpd1 sphingomyelin phosphodiesterase 1 multiple interactions ISO [vorinostat co-treated with sorafenib] promotes the reaction [SMPD1 protein results in increased abundance of Ceramides]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein] CTD PMID:18787411 NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] CTD PMID:21360571 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969 		JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions
decreases expression		 ISO destruxin B promotes the reaction [sorafenib results in decreased expression of SNAI2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of SNAI2 protein] CTD PMID:24434019 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Snd1 staphylococcal nuclease and tudor domain containing 1 decreases response to substance ISO SND1 protein results in decreased susceptibility to Sorafenib CTD PMID:37927237 NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843 		JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO sorafenib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression		 ISO bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein] CTD PMID:21858812 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases activity		 ISO sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased activity of SRC protein		 CTD PMID:20881478 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
decreases phosphorylation
affects localization		 ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Acids results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of STAT3 protein
sorafenib analog results in decreased phosphorylation of STAT3 protein; sorafenib results in decreased phosphorylation of STAT3 protein
sorafenib affects the localization of STAT3 protein		 CTD PMID:18512153 PMID:19001435 PMID:20881478 PMID:21360571 PMID:21531053 More... NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
decreases activity
multiple interactions		 ISO sorafenib results in decreased phosphorylation of STAT5A protein
sorafenib results in decreased activity of STAT5A protein
resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5A protein]		 CTD PMID:17595328 PMID:23036488 PMID:26911335 NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5B protein] CTD PMID:26911335 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668 		JBrowse link
G Stc1 stanniocalcin 1 decreases expression
multiple interactions		 ISO sorafenib results in decreased expression of STC1 mRNA
STC1 affects the reaction [sorafenib results in increased abundance of Reactive Oxygen Species]		 CTD PMID:25370841 NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264 		JBrowse link
G Tbx3 T-box transcription factor 3 decreases expression ISO sorafenib decreases expression of TBX3 mRNA in liver RGD PMID:22811581 RGD:151361132 NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases activity
decreases expression		 ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TGFB1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased activity of TGFB1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
sorafenib results in decreased expression of TGFB1 mRNA		 CTD PMID:21360571 PMID:29859236 PMID:32918399 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TIMP1 mRNA] CTD PMID:32918399 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO sorafenib results in decreased expression of TIMP3 mRNA CTD PMID:21360571 NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein] CTD PMID:21360571 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein]
Sorafenib inhibits the reaction [Oleic Acid results in increased expression of TNF protein]		 CTD PMID:29859236 PMID:32918399 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases response to substance		 ISO [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; [Sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein; [Sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]
sorafenib results in increased susceptibility to TNFSF10 protein		 CTD PMID:17909059 PMID:20071162 PMID:21601561 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein] CTD PMID:17991738 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Trim62 tripartite motif-containing 62 affects response to substance ISO TRIM62 protein affects the susceptibility to Sorafenib CTD PMID:35469851 NCBI chr 5:141,230,830...141,260,629
Ensembl chr 5:141,231,523...141,259,915 		JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein] CTD PMID:21813464 NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases expression ISO sorafenib results in decreased expression of TWIST1 mRNA CTD PMID:21360571 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653 		JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO sorafenib results in increased expression of TXNRD1 mRNA CTD PMID:26409325 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO
EXP		 Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein] CTD PMID:29859236 PMID:36731809 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vim vimentin multiple interactions
decreases expression		 ISO destruxin B promotes the reaction [sorafenib results in decreased expression of VIM protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of VIM protein] CTD PMID:21360571 PMID:24434019 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
G Xbp1 X-box binding protein 1 increases splicing ISO sorafenib results in increased splicing of XBP1 mRNA CTD PMID:17548474 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
multiple interactions
increases cleavage		 ISO sorafenib results in decreased expression of XIAP protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein
sorafenib results in increased cleavage of XIAP protein		 CTD PMID:16109713 PMID:17909059 PMID:18200035 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700 		JBrowse link
G Yap1 Yes1 associated transcriptional regulator decreases response to substance ISO YAP1 protein results in decreased susceptibility to sorafenib CTD PMID:29698666 NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010 		JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 decreases expression ISO sorafenib results in decreased expression of ZEB1 mRNA CTD PMID:21360571 NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214 		JBrowse link
G Zeb2 zinc finger E-box binding homeobox 2 decreases expression ISO sorafenib results in decreased expression of ZEB2 mRNA CTD PMID:21360571 NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19880
    role 19850
      biological role 19848
        biochemical role 19556
          ferroptosis inducer 15743
            sorafenib 193
              sorafenib tosylate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19880
    subatomic particle 19878
      composite particle 19878
        hadron 19878
          baryon 19878
            nucleon 19878
              atomic nucleus 19878
                atom 19878
                  main group element atom 19817
                    p-block element atom 19817
                      carbon group element atom 19757
                        carbon atom 19754
                          organic molecular entity 19754
                            heteroorganic entity 19512
                              organochalcogen compound 19275
                                organooxygen compound 19191
                                  carbon oxoacid 18658
                                    carboxylic acid 18655
                                      carboacyl group 17699
                                        univalent carboacyl group 17699
                                          carbamoyl group 17550
                                            carboxamide 17550
                                              monocarboxylic acid amide 15732
                                                urea 6222
                                                  ureas 6220
                                                    phenylureas 2620
                                                      sorafenib 193
                                                        sorafenib tosylate 0
paths to the root